This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

In this article

RIGL

Follow your favorite stocks CREATE FREE ACCOUNT

It's been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals , which has approved treatments for hematology and oncology — as well as potential new drugs in the pipeline.

The stock has jumped about 50% in just the last three months, earning it a spot on CNBC's list of top performing stocks of companies based in the City by the Bay. To find the stocks, CNBC screened for names based in the area that had market caps above $500 million. We then screened for the top performers over the last three months via FactSet.

"We have a business that's growing substantially," CEO Raul Rodriguez said in an interview with CNBC's Brian Sullivan. "[We] grew 30% on average for four